Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Gimsilumab in Healthy Volunteers and AS Patients
NCT04205851Phase 1Completed
- Sponsor
- Kinevant Sciences
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gimsilumab in ankylosing spondylitis (AS) (2 arms), sponsored by Kinevant Sciences. Primary endpoints: Incidence of treatment-emergent adverse events up to 78 days, Change from baseline in QTcF interval up to 78 days and 2 more. Started Nov 2019; status: completed.
02
Drugs
gimsilumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04205851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205851.